

Alexandria P Cogdill

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1877297/publications.pdf>

Version: 2024-02-01

29
papers

15,457
citations

236612

25
h-index

476904

29
g-index

30
all docs

30
docs citations

30
times ranked

22270
citing authors

#	ARTICLE	IF	CITATIONS
1	Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. <i>Science</i> , 2018, 359, 97-103.	6.0	3,126
2	B cells and tertiary lymphoid structures promote immunotherapy response. <i>Nature</i> , 2020, 577, 549-555.	13.7	1,421
3	COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. <i>Nature</i> , 2010, 468, 968-972.	13.7	1,325
4	Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. <i>Blood</i> , 2009, 114, 535-546.	0.6	1,280
5	The human tumor microbiome is composed of tumor type-specific intracellular bacteria. <i>Science</i> , 2020, 368, 973-980.	6.0	1,077
6	Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade. <i>Cell</i> , 2017, 170, 1120-1133.e17.	13.5	960
7	EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib. <i>Cancer Discovery</i> , 2012, 2, 227-235.	7.7	852
8	BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2013, 19, 1225-1231.	3.2	832
9	Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function. <i>Cancer Research</i> , 2010, 70, 5213-5219.	0.4	659
10	Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. <i>Nature</i> , 2018, 558, 307-312.	13.7	574
11	Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma. <i>Immunity</i> , 2016, 44, 1444-1454.	6.6	458
12	Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice. <i>Cancer Research</i> , 2015, 75, 3596-3607.	0.4	426
13	Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. <i>Blood</i> , 2016, 127, 1117-1127.	0.6	381
14	Rational development and characterization of humanized EGFR variant III chimeric antigen receptor T cells for glioblastoma. <i>Science Translational Medicine</i> , 2015, 7, 275ra22.	5.8	369
15	Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. <i>Science</i> , 2021, 374, 1632-1640.	6.0	369
16	Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment. <i>Cell</i> , 2021, 184, 5338-5356.e21.	13.5	229
17	Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 22699-22709.	3.3	226
18	Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. <i>Nature Medicine</i> , 2021, 27, 1432-1441.	15.2	216

#	ARTICLE	IF	CITATIONS
19	Hallmarks of response to immune checkpoint blockade. <i>British Journal of Cancer</i> , 2017, 117, 1-7.	2.9	194
20	Checkpoint Blockade Reverses Anergy in IL-13R α 2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine Gliomas. <i>Molecular Therapy - Oncolytics</i> , 2018, 11, 20-38.	2.0	123
21	Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. <i>Npj Genomic Medicine</i> , 2017, 2, .	1.7	120
22	The Impact of Intratumoral and Gastrointestinal Microbiota on Systemic Cancer Therapy. <i>Trends in Immunology</i> , 2018, 39, 900-920.	2.9	56
23	Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. <i>Nature</i> , 2022, 606, 797-803.	13.7	54
24	The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid Malignancies. <i>Annals of Surgical Oncology</i> , 2018, 25, 1814-1827.	0.7	45
25	Hallmarks of Resistance to Immune-Checkpoint Inhibitors. <i>Cancer Immunology Research</i> , 2022, 10, 372-383.	1.6	36
26	Potential role of 5-Aza-2â€²-deoxycytidine induced MAGE-A4 expression in immunotherapy for anaplastic thyroid cancer. <i>Surgery</i> , 2013, 154, 1456-1462.	1.0	23
27	Targeting the MAGE A3 antigen in pancreatic cancer. <i>Surgery</i> , 2012, 152, S13-S18.	1.0	18
28	Elucidating the gut microbiota composition and the bioactivity of immunostimulatory commensals for the optimization of immune checkpoint inhibitors. <i>Oncolmunology</i> , 2020, 9, 1794423.	2.1	7
29	Gene Targeting Meets Cell-Based Therapy: Raising the Tail, or Merely a Whimper?. <i>Clinical Cancer Research</i> , 2017, 23, 327-329.	3.2	1